Oral hypoglycemic agent
Oral hypoglycemic agents are a class of medications used in the management of diabetes mellitus that are taken by mouth to lower blood glucose levels. They are commonly used in the treatment of Type 2 diabetes, a condition characterized by insulin resistance and/or reduced insulin secretion. These agents work through various mechanisms to help control blood sugar levels in patients with diabetes.
Types of Oral Hypoglycemic Agents[edit | edit source]
Oral hypoglycemic agents can be classified into several categories based on their mechanism of action:
Sulfonylureas[edit | edit source]
Sulfonylureas, such as glimepiride, glipizide, and glyburide, act by increasing insulin secretion from the pancreas. They bind to and close potassium channels on the pancreatic beta cells, which leads to cell depolarization and insulin release.
Biguanides[edit | edit source]
Metformin is the most commonly used biguanide. It works by decreasing glucose production in the liver and improving insulin sensitivity, which enhances glucose uptake by the muscles.
Thiazolidinediones[edit | edit source]
Thiazolidinediones, including pioglitazone and rosiglitazone, work by increasing insulin sensitivity in peripheral tissues, making it easier for cells to utilize glucose.
DPP-4 Inhibitors[edit | edit source]
Dipeptidyl peptidase-4 (DPP-4) inhibitors, such as sitagliptin, saxagliptin, and linagliptin, work by blocking the DPP-4 enzyme, which results in increased levels of incretin hormones. These hormones help to regulate glucose by increasing insulin release and decreasing glucagon levels in the presence of high blood glucose.
SGLT2 Inhibitors[edit | edit source]
Sodium-glucose cotransporter 2 (SGLT2) inhibitors, like canagliflozin, dapagliflozin, and empagliflozin, reduce blood glucose by blocking glucose reabsorption in the kidney, leading to increased glucose excretion in the urine.
Meglitinides[edit | edit source]
Meglitinides, such as repaglinide and nateglinide, stimulate insulin secretion from the pancreas but have a shorter duration of action compared to sulfonylureas.
Indications[edit | edit source]
Oral hypoglycemic agents are primarily indicated for the management of Type 2 diabetes in adults. They are often used in combination with diet and exercise to achieve better glucose control. In some cases, they may be used in combination with other oral agents or with insulin therapy.
Side Effects[edit | edit source]
The side effects of oral hypoglycemic agents vary depending on the specific medication. Common side effects include hypoglycemia (low blood sugar), gastrointestinal disturbances, weight gain, and risk of cardiovascular events. Monitoring and dose adjustments are essential to minimize these risks.
Conclusion[edit | edit source]
Oral hypoglycemic agents play a crucial role in the management of Type 2 diabetes. Understanding the various types of agents and their mechanisms of action can help healthcare providers tailor treatment plans to meet the individual needs of their patients.
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD